Virginia Espina

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/38569/virginia-espina-publications-by-year.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

156 papers 10,087 d8 papers h-index 99 g-index

161 10,982 6.1 5.33 ext. papers ext. citations avg, IF L-index

#	Paper	IF	Citations
156	Reverse Phase Protein Arrays. <i>Methods in Molecular Biology</i> , 2021 , 2237, 103-122	1.4	
155	Laser Capture Proteomics: Spatial Tissue Molecular Profiling from the bench to personalized medicine. <i>Expert Review of Proteomics</i> , 2021 ,	4.2	3
154	Protocol for the Mason: Health Starts Here prospective cohort study of young adult college students. <i>BMC Public Health</i> , 2021 , 21, 897	4.1	4
153	Local production of lactate, ribose phosphate, and amino acids within human triple-negative breast cancer. <i>Med</i> , 2021 , 2, 736-754	31.7	6
152	Effects of HER Family-targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer. <i>Clinical Cancer Research</i> , 2021 , 27, 807-818	12.9	8
151	Proteomic Analysis of Cardioembolic and Large Artery Atherosclerotic Clots Using Reverse Phase Protein Array Technology Reveals Key Cellular Interactions Within Clot Microenvironments. <i>Cureus</i> , 2021 , 13, e13499	1.2	1
150	Encouraging long-term survival following autophagy inhibition using neoadjuvant hydroxychloroquine and gemcitabine for high-risk patients with resectable pancreatic carcinoma. <i>Cancer Medicine</i> , 2021 , 10, 7233-7241	4.8	3
149	Evaluation of pathogen specific urinary peptides in tick-borne illnesses. Scientific Reports, 2020, 10, 193	40 9	2
148	A Randomized Phase II Preoperative Study of Autophagy Inhibition with High-Dose Hydroxychloroquine and Gemcitabine/Nab-Paclitaxel in Pancreatic Cancer Patients. <i>Clinical Cancer Research</i> , 2020 , 26, 3126-3134	12.9	64
147	Clinical proteomics and molecular pathology 2020 , 149-163		
146	Lipoarabinomannan antigenic epitope differences in tuberculosis disease subtypes. <i>Scientific Reports</i> , 2020 , 10, 13944	4.9	2
145	Tumor-Draining Lymph Secretome En Route to the Regional Lymph Node in Breast Cancer Metastasis. <i>Breast Cancer: Targets and Therapy</i> , 2020 , 12, 57-67	3.9	2
144	Characterization and Validation of Arg286 Residue of IL-1RAcP as a Potential Drug Target for Osteoarthritis. <i>Frontiers in Chemistry</i> , 2020 , 8, 601477	5	O
143	Proteomics for cancer drug design. Expert Review of Proteomics, 2019, 16, 647-664	4.2	3
142	Solid Pin Protein Array Printing Platforms. <i>Advances in Experimental Medicine and Biology</i> , 2019 , 1188, 61-75	3.6	
141	RPPA: Origins, Transition to a Validated Clinical Research Tool, and Next Generations of the Technology. <i>Advances in Experimental Medicine and Biology</i> , 2019 , 1188, 1-19	3.6	8
140	Comutation of and in Residual Disease After Preoperative Anti-HER2 Therapy in ERBB2 (HER2)-Amplified Early Breast Cancer <i>JCO Precision Oncology</i> , 2019 , 3, 1-26	3.6	1

139	Different measures of HMGB1 location in cancer immunology. <i>Methods in Enzymology</i> , 2019 , 629, 195-2	1 17.7	5
138	A new model isolates glioblastoma clonal interactions and reveals unexpected modes for regulating motility, proliferation, and drug resistance. <i>Scientific Reports</i> , 2019 , 9, 17380	4.9	9
137	Unlocking bone for proteomic analysis and FISH. <i>Laboratory Investigation</i> , 2019 , 99, 708-721	5.9	2
136	Protein biomarkers for subtyping breast cancer and implications for future research. <i>Expert Review of Proteomics</i> , 2018 , 15, 131-152	4.2	35
135	Stromal TRIM28-associated signaling pathway modulation within the colorectal cancer microenvironment. <i>Journal of Translational Medicine</i> , 2018 , 16, 89	8.5	5
134	Clinical Proteomics and Molecular Pathology 2018 , 183-203		
133	Combination Kinase Inhibitor Treatment Suppresses Rift Valley Fever Virus Replication. <i>Viruses</i> , 2018 , 10,	6.2	4
132	Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL. <i>BMC Cancer</i> , 2018 , 18, 965	4.8	13
131	Pathology-Driven Comprehensive Proteomic Profiling of the Prostate Cancer Tumor Microenvironment. <i>Molecular Cancer Research</i> , 2017 , 15, 281-293	6.6	15
130	Dual-Color, Multiplex Analysis of Protein Microarrays for Precision Medicine. <i>Methods in Molecular Biology</i> , 2017 , 1550, 149-170	1.4	2
129	One-Step Preservation and Decalcification of Bony Tissue for Molecular Profiling. <i>Methods in Molecular Biology</i> , 2017 , 1606, 85-102	1.4	2
128	Rapamycin modulation of p70 S6 kinase signaling inhibits Rift Valley fever virus pathogenesis. <i>Antiviral Research</i> , 2017 , 143, 162-175	10.8	14
127	Potential anti-cancer activity of 7-O-pentyl quercetin: Efficient, membrane-targeted kinase inhibition and pro-oxidant effect. <i>Pharmacological Research</i> , 2017 , 124, 9-19	10.2	8
126	Proteomic Analysis Reveals Autophagy as Pro-Survival Pathway Elicited by Long-Term Exposure with 5-Azacitidine in High-Risk Myelodysplasia. <i>Frontiers in Pharmacology</i> , 2017 , 8, 204	5.6	10
125	Immune-modulating Activity of Hydrogel Microparticles Contributes to the Host Defense in a Murine Model of Cutaneous Anthrax. <i>Frontiers in Molecular Biosciences</i> , 2017 , 4, 62	5.6	О
124	A preclinical evaluation of the MEK inhibitor refametinib in HER2-positive breast cancer cell lines including those with acquired resistance to trastuzumab or lapatinib. <i>Oncotarget</i> , 2017 , 8, 85120-85135	3.3	11
123	Persistent CD49d engagement in circulating CLL cells: a role for blood-borne ligands?. <i>Leukemia</i> , 2016 , 30, 513-7	10.7	2
122	Treatment and Long-Term Risks for Patients With a Diagnosis of Ductal Carcinoma In Situ. <i>JAMA Oncology</i> , 2016 , 2, 395	13.4	1

121	PMCA2 regulates HER2 protein kinase localization and signaling and promotes HER2-mediated breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016 , 113, E282-90	11.5	51
120	Chemokine-Releasing Microparticles Improve Bacterial Clearance and Survival of Anthrax Spore-Challenged Mice. <i>PLoS ONE</i> , 2016 , 11, e0163163	3.7	4
119	Current state of the art for enhancing urine biomarker discovery. <i>Expert Review of Proteomics</i> , 2016 , 13, 609-26	4.2	60
118	Safety and Biologic Response of Pre-operative Autophagy Inhibition in Combination with Gemcitabine in Patients with Pancreatic Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2015 , 22, 4402-	10 ^{3.1}	138
117	Chemokine-Releasing Nanoparticles for Manipulation of Lymph Node Microenvironment. <i>Nanomaterials</i> , 2015 , 5, 298-320	5.4	8
116	High CerS5 expression levels associate with reduced patient survival and transition from apoptotic to autophagy signalling pathways in colorectal cancer. <i>Journal of Pathology: Clinical Research</i> , 2015 , 1, 54-65	5.3	16
115	Application of Nanotrap technology for high sensitivity measurement of urinary outer surface protein A carboxyl-terminus domain in early stage Lyme borreliosis. <i>Journal of Translational Medicine</i> , 2015 , 13, 346	8.5	40
114	Nitric oxide as a regulator of B. anthracis pathogenicity. <i>Frontiers in Microbiology</i> , 2015 , 6, 921	5.7	9
113	Reverse-Phase Microarray Analysis Reveals Novel Targets in Lymph Nodes of Bacillus anthracis Spore-Challenged Mice. <i>PLoS ONE</i> , 2015 , 10, e0129860	3.7	6
112	Glioblastoma cell enrichment is critical for analysis of phosphorylated drug targets and proteomic-genomic correlations. <i>Cancer Research</i> , 2014 , 74, 818-28	10.1	37
111	Stratification of clear cell renal cell carcinoma by signaling pathway analysis. <i>Expert Review of Proteomics</i> , 2014 , 11, 237-49	4.2	8
110	Protein painting reveals solvent-excluded drug targets hidden within native protein-protein interfaces. <i>Nature Communications</i> , 2014 , 5, 4413	17.4	36
109	Non-enzymatic, serum-free tissue culture of pre-invasive breast lesions for spontaneous generation of mammospheres. <i>Journal of Visualized Experiments</i> , 2014 , e51926	1.6	
108	Hydrogel nanoparticle harvesting of plasma or urine for detecting low abundance proteins. <i>Journal of Visualized Experiments</i> , 2014 , e51789	1.6	8
107	Inhibition of histone deacetylase 4 increases cytotoxicity of docetaxel in gastric cancer cells. Proteomics - Clinical Applications, 2014 , 8, 924-31	3.1	19
106	Reverse phase protein arrays: mapping the path towards personalized medicine. <i>Molecular Diagnosis and Therapy</i> , 2014 , 18, 619-30	4.5	31
105	Students who demonstrate strong talent and interest in STEM are initially attracted to STEM through extracurricular experiences. <i>CBE Life Sciences Education</i> , 2014 , 13, 687-97	3.4	30
104	Mapping protein signal pathway interaction in sarcoma bone metastasis: linkage between rank, metalloproteinases turnover and growth factor signaling pathways. <i>Clinical and Experimental Metastasis</i> , 2014 , 31, 15-24	4.7	20

103	Whole proteome analysis of mouse lymph nodes in cutaneous anthrax. <i>PLoS ONE</i> , 2014 , 9, e110873	3.7	9
102	Reverse Phase Protein Microarray Technology: Advances into the Clinical Research Arena 2013 , 349-367	1	
101	Laser capture microdissection for protein and NanoString RNA analysis. <i>Methods in Molecular Biology</i> , 2013 , 931, 213-57	1.4	40
100	Retinal pigment epithelium (RPE) exosomes contain signaling phosphoproteins affected by oxidative stress. <i>Experimental Cell Research</i> , 2013 , 319, 2113-2123	4.2	80
99	Pathologic complete response after preoperative anti-HER2 therapy correlates with alterations in PTEN, FOXO, phosphorylated Stat5, and autophagy protein signaling. <i>BMC Research Notes</i> , 2013 , 6, 507	2.3	47
98	Attacking breast cancer at the preinvasion stage by targeting autophagy. Womenls Health, 2013, 9, 157-	-730	8
97	Elevated TNFR1 and serotonin in bone metastasis are correlated with poor survival following bone metastasis diagnosis for both carcinoma and sarcoma primary tumors. <i>Clinical Cancer Research</i> , 2013 , 19, 2473-85	12.9	28
96	Chloroquine enjoys a renaissance as an antineoplastic therapy. Clinical Investigation, 2013, 3, 743-761		2
95	Molecular analysis of HER2 signaling in human breast cancer by functional protein pathway activation mapping. <i>Clinical Cancer Research</i> , 2012 , 18, 6426-35	12.9	88
94	Reduction of preanalytical variability in specimen procurement for molecular profiling. <i>Methods in Molecular Biology</i> , 2012 , 823, 49-57	1.4	13
93	Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy, 2012, 8, 445-	5 46 .2	2783
92	Ductal carcinoma in situ: challenges, opportunities, and uncharted waters. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2012 , 40-4	7.1	5
91	Improved data normalization methods for reverse phase protein microarray analysis of complex biological samples. <i>BioTechniques</i> , 2012 , 1-7	2.5	23
90	Application of Analyte Harvesting Nanoparticle Technology to the Measurement of Urinary HGH in Healthy Individuals 2012 , 2,		8
89	Laser capture microdissection: Arcturus(XT) infrared capture and UV cutting methods. <i>Methods in Molecular Biology</i> , 2012 , 823, 157-78	1.4	23
88	Circulating CLL Cells Expressing CD49d Display a Phospho-Proteomic Profile Consistent with a Constitutive Receptor Engagement by Blood-Borne Ligands. <i>Blood</i> , 2012 , 120, 930-930	2.2	
87	Multifunctional core-shell nanoparticles: discovery of previously invisible biomarkers. <i>Journal of the American Chemical Society</i> , 2011 , 133, 19178-88	16.4	79
86	Phosphoprotein stability in clinical tissue and its relevance for reverse phase protein microarray technology. <i>Methods in Molecular Biology</i> , 2011 , 785, 23-43	1.4	23

85	A novel biomarker harvesting nanotechnology identifies Bak as a candidate melanoma biomarker in serum. <i>Experimental Dermatology</i> , 2011 , 20, 29-34	4	39
84	A response to the two faces of autophagy in DCIS. <i>Nature Reviews Cancer</i> , 2011 , 11, 618-618	31.3	
83	What is the malignant nature of human ductal carcinoma in situ?. <i>Nature Reviews Cancer</i> , 2011 , 11, 68-7	'531.3	82
82	The use of hydrogel microparticles to sequester and concentrate bacterial antigens in a urine test for Lyme disease. <i>Biomaterials</i> , 2011 , 32, 1157-66	15.6	41
81	One-step preservation of phosphoproteins and tissue morphology at room temperature for diagnostic and research specimens. <i>PLoS ONE</i> , 2011 , 6, e23780	3.7	66
80	Reverse phase protein microarrays: fluorometric and colorimetric detection. <i>Methods in Molecular Biology</i> , 2011 , 723, 275-301	1.4	14
79	Proteomic and Genomic Profile of High-Risk MDS After Treatment with 5-Azacytidine,. <i>Blood</i> , 2011 , 118, 3818-3818	2.2	
78	Clinical Proteomics and Molecular Pathology 2010 , 113-123		
77	Functional protein network activation mapping reveals new potential molecular drug targets for poor prognosis pediatric BCP-ALL. <i>PLoS ONE</i> , 2010 , 5, e13552	3.7	38
76	Reverse-phase phosphoproteome analysis of signaling pathways induced by Rift valley fever virus in human small airway epithelial cells. <i>PLoS ONE</i> , 2010 , 5, e13805	3.7	42
75	Tumorigenic and metastatic activity of human thyroid cancer stem cells. Cancer Research, 2010, 70, 887	′4 <u>185</u> 1	177
74	Reverse phase protein microarrays advance to use in clinical trials. <i>Molecular Oncology</i> , 2010 , 4, 461-81	7.9	112
73	The heme degradation pathway is a promising serum biomarker source for the early detection of Alzheimer's disease. <i>Journal of Alzheimerls Disease</i> , 2010 , 19, 1081-91	4.3	45
72	Malignant precursor cells pre-exist in human breast DCIS and require autophagy for survival. <i>PLoS ONE</i> , 2010 , 5, e10240	3.7	109
71	Treatment with TKIs Overcomes Imatinib Resistance through the PLCgamma-1 Signaling Pathway In Imatinib Resistant Human CML Cell Lines. <i>Blood</i> , 2010 , 116, 4468-4468	2.2	
70	Serotonin Dysregulation Correlates with Both Bone and Active Disease In Multiple Myeloma. <i>Blood</i> , 2010 , 116, 1920-1920	2.2	
69	Clinical Proteomics and Molecular Pathology 2009 , 165-183		2
68	Core-shell hydrogel particles harvest, concentrate and preserve labile low abundance biomarkers. <i>PLoS ONE</i> , 2009 , 4, e4763	3.7	82

(2008-2009)

67	Activated VEGF receptor shed into the vitreous in eyes with wet AMD: a new class of biomarkers in the vitreous with potential for predicting the treatment timing and monitoring response. <i>JAMA Ophthalmology</i> , 2009 , 127, 613-21		31
66	Quantitative cell signalling analysis reveals down-regulation of MAPK pathway activation in colorectal cancer. <i>Journal of Pathology</i> , 2009 , 218, 514-9	9.4	47
65	Tissue is alive: New technologies are needed to address the problems of protein biomarker pre-analytical variability. <i>Proteomics - Clinical Applications</i> , 2009 , 3, 874-882	3.1	75
64	Anthrax infection inhibits the AKT signaling involved in the E-cadherin-mediated adhesion of lung epithelial cells. <i>FEMS Immunology and Medical Microbiology</i> , 2009 , 56, 129-42		20
63	Reverse-phase protein microarrays for theranostics and patient tailored therapy. <i>Methods in Molecular Biology</i> , 2009 , 520, 89-105	1.4	24
62	Nanoparticle technology: amplifying the effective sensitivity of biomarker detection to create a urine test for hGH. <i>Drug Testing and Analysis</i> , 2009 , 1, 447-54	3.5	24
61	Nanoparticle technology: Addressing the fundamental roadblocks to protein biomarker discovery. Journal of Materials Chemistry, 2009 , 19, 5071-5077		21
60	Application of laser microdissection and reverse-phase protein microarrays to the molecular profiling of cancer signal pathway networks in the tissue microenvironment. <i>Clinics in Laboratory Medicine</i> , 2009 , 29, 1-13	2.1	28
59	Comparison of global versus epidermal growth factor receptor pathway profiling for prediction of lapatinib sensitivity in bladder cancer. <i>Neoplasia</i> , 2009 , 11, 1185-93	6.4	26
58	Ex Vivo Multiplexed Signal Pathway Inhibitor Treatment Reveals Differential Sensitivity of Myeloma and Non-Myeloma Bone Marrow Cell Populations <i>Blood</i> , 2009 , 114, 2860-2860	2.2	
57	Smart hydrogel particles: biomarker harvesting: one-step affinity purification, size exclusion, and protection against degradation. <i>Nano Letters</i> , 2008 , 8, 350-61	11.5	159
56	Multiplexed cell signaling analysis of human breast cancer applications for personalized therapy. Journal of Proteome Research, 2008, 7, 1508-17	5.6	113
55	A portrait of tissue phosphoprotein stability in the clinical tissue procurement process. <i>Molecular and Cellular Proteomics</i> , 2008 , 7, 1998-2018	7.6	165
54	Laser capture microdissection and protein microarray analysis of human non-small cell lung cancer: differential epidermal growth factor receptor (EGPR) phosphorylation events associated with mutated EGFR compared with wild type. <i>Molecular and Cellular Proteomics</i> , 2008 , 7, 1902-24	7.6	93
53	Concentration and Preservation of Very Low Abundance Biomarkers in Urine, such as Human Growth Hormone (hGH), by Cibacron Blue F3G-A Loaded Hydrogel Particles. <i>Nano Research</i> , 2008 , 1, 50	2 ⁻¹⁵ 18	49
52	Clinical Proteomics 2008 , 231-239		
51	Automated laser capture microdissection for tissue proteomics. <i>Methods in Molecular Biology</i> , 2008 , 441, 71-90	1.4	16
50	Reverse phase protein microarrays for theranostics and patient-tailored therapy. <i>Methods in Molecular Biology</i> , 2008 , 441, 113-28	1.4	22

49	Molecular network analysis using reverse phase protein microarrays for patient tailored therapy. <i>Advances in Experimental Medicine and Biology</i> , 2008 , 610, 177-86	3.6	14
48	Reverse-phase protein microarrays: application to biomarker discovery and translational medicine. <i>Expert Review of Molecular Diagnostics</i> , 2007 , 7, 625-33	3.8	69
47	A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer. <i>Cancer</i> , 2007 , 109, 1323-30	6.4	124
46	The needle in the haystack: application of breast fine-needle aspirate samples to quantitative protein microarray technology. <i>Cancer</i> , 2007 , 111, 173-84	6.4	66
45	A prospective analysis of imatinib-induced c-KIT modulation in ovarian cancer: a phase II clinical study with proteomic profiling. <i>Cancer</i> , 2007 , 110, 309-17	6.4	57
44	Physicochemically modified silicon as a substrate for protein microarrays. <i>Biomaterials</i> , 2007 , 28, 550-8	15.6	61
43	Phosphoprotein pathway mapping: Akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival. <i>Cancer Research</i> , 2007 , 67, 3431-40	10.1	210
42	Laser capture microdissection technology. Expert Review of Molecular Diagnostics, 2007, 7, 647-57	3.8	140
41	Reverse phase protein microarrays for monitoring biological responses. <i>Methods in Molecular Biology</i> , 2007 , 383, 321-36	1.4	25
40	Development of reverse phase protein microarrays for clinical applications and patient-tailored therapy. <i>Cancer Genomics and Proteomics</i> , 2007 , 4, 157-64	3.3	12
39	Clinical phosphoproteomic profiling for personalized targeted medicine using reverse phase protein microarray. <i>Targeted Oncology</i> , 2006 , 1, 151	5	2
38	Accurate diagnosis of acute graft-versus-host disease using serum proteomic pattern analysis. <i>Experimental Hematology</i> , 2006 , 34, 796-801	3.1	53
37	Proteomic analysis of malignant ovarian cancer effusions as a tool for biologic and prognostic profiling. <i>Clinical Cancer Research</i> , 2006 , 12, 791-9	12.9	68
36	Role of proteomics in personalized medicine. <i>Personalized Medicine</i> , 2006 , 3, 223-226	2.2	2
35	Laser-capture microdissection. <i>Nature Protocols</i> , 2006 , 1, 586-603	18.8	504
34	Proteomics of breast cancer 2006 , 101-113		
33	Alterations of Cell Signaling Pathways in Pediatric B-ALL Patients <i>Blood</i> , 2006 , 108, 4427-4427	2.2	
32	Laser capture microdissection. <i>Methods in Molecular Biology</i> , 2006 , 319, 213-29	1.4	50

(2004-2005)

31	Pegylated, steptavidin-conjugated quantum dots are effective detection elements for reverse-phase protein microarrays. <i>Bioconjugate Chemistry</i> , 2005 , 16, 559-66	6.3	113
30	Pathology of the Future: Molecular Profiling for Targeted Therapy. <i>Cancer Investigation</i> , 2005 , 23, 36-46	2.1	58
29	CSF proteome: a protein repository for potential biomarker identification. <i>Expert Review of Proteomics</i> , 2005 , 2, 57-70	4.2	99
28	Protein pathway analysis in Clinical Proteomics using protein microarrays. <i>Drug Discovery Today: Technologies</i> , 2005 , 2, 353-9	7.1	1
27	Expression of xeroderma pigmentosum A protein predicts improved outcome in metastatic ovarian carcinoma. <i>Cancer</i> , 2005 , 103, 2313-9	6.4	28
26	Manual exfoliation of fresh tissue obviates the need for frozen sections for molecular profiling. <i>Cancer</i> , 2005 , 105, 483-91	6.4	6
25	An Interventional Magnetic Resonance Imaging Technique for the Molecular Characterization of Intraprostatic Dynamic Contrast Enhancement. <i>Molecular Imaging</i> , 2005 , 4, 153535002005041	3.7	14
24	A transforming growth factor-beta receptor-interacting protein frequently mutated in human ovarian cancer. <i>Cancer Research</i> , 2005 , 65, 6526-33	10.1	55
23	Mapping molecular networks using proteomics: a vision for patient-tailored combination therapy. Journal of Clinical Oncology, 2005 , 23, 3614-21	2.2	158
22	Proteomic analysis of apoptotic pathways reveals prognostic factors in follicular lymphoma. <i>Clinical Cancer Research</i> , 2005 , 11, 5847-55	12.9	99
21	Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma. <i>Molecular and Cellular Proteomics</i> , 2005 , 4, 346-55	7.6	244
20	Adipocyte-derived collagen VI affects early mammary tumor progression in vivo, demonstrating a critical interaction in the tumor/stroma microenvironment. <i>Journal of Clinical Investigation</i> , 2005 , 115, 1163-76	15.9	274
19	An interventional magnetic resonance imaging technique for the molecular characterization of intraprostatic dynamic contrast enhancement. <i>Molecular Imaging</i> , 2005 , 4, 63-6	3.7	7
18	Pathology of the future: molecular profiling for targeted therapy. <i>Cancer Investigation</i> , 2005 , 23, 36-46	2.1	8
17	Application of laser capture microdissection and protein microarray technologies in the molecular analysis of airway injury following pollution particle exposure. <i>Journal of Toxicology and Environmental Health - Part A: Current Issues</i> , 2004 , 67, 851-61	3.2	12
16	Use of proteomic patterns to screen for gastrointestinal malignancies. <i>Surgery</i> , 2004 , 135, 243-7	3.6	28
15	Protein microarray detection strategies: focus on direct detection technologies. <i>Journal of Immunological Methods</i> , 2004 , 290, 121-33	2.5	157
14	Application of sector protein microarrays to clinical samples. <i>Clinical Proteomics</i> , 2004 , 1, 91-99	5	4

13	Use of proteomic analysis to monitor responses to biological therapies. <i>Expert Opinion on Biological Therapy</i> , 2004 , 4, 83-93	5.4	77
12	Serum proteomics in cancer diagnosis and management. <i>Annual Review of Medicine</i> , 2004 , 55, 97-112	17.4	116
11	Clinical proteomics: revolutionizing disease detection and patient tailoring therapy. <i>Journal of Proteome Research</i> , 2004 , 3, 209-17	5.6	96
10	Genomic and proteomic technologies for individualisation and improvement of cancer treatment. <i>European Journal of Cancer</i> , 2004 , 40, 2623-32	7.5	77
9	Biomarkers of ovarian tumours. European Journal of Cancer, 2004, 40, 2604-12	7.5	68
8	Protein Microarrays 2004 , 1083-1088		
7	Molecular diagnostics. Hematology American Society of Hematology Education Program, 2003, 2003, 279)-93:	17
6	Protein microarrays: meeting analytical challenges for clinical applications. <i>Cancer Cell</i> , 2003 , 3, 317-25	24.3	400
5	Protein microarrays: molecular profiling technologies for clinical specimens. <i>Proteomics</i> , 2003 , 3, 2091-	10,08	209
4	Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003 , 100, 14229-34	11.5	415
3	Applications of Proteomics to Metastasis Diagnosis and Individualized Therapy475-485		
2	Development and Use of Reversed-Phase Protein Microarrays for Clinical Applications165-175		
1	Pathology of the Future: Molecular Profiling for Targeted Therapy		3